Skip to main content
Top
Published in: BMC Geriatrics 1/2015

Open Access 01-12-2015 | Research article

A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents

Authors: Andrea Foebel, Anna Ballokova, Nathalie IH Wellens, Daniela Fialova, Koen Milisen, Rosa Liperoti, John P Hirdes

Published in: BMC Geriatrics | Issue 1/2015

Login to get access

Abstract

Background

Use of antipsychotic (AP) medications is high and often inappropriate among institutionalized populations. Little is known about the correlates of new AP drug use following admission to long-term care (LTC) settings. This study investigated the frequency and correlates of new AP drug use among newly admitted LTC residents.

Methods

This longitudinal, retrospective study used data from the interRAI - Nursing Home Minimum Data Set version 2.0 (MDS 2.0) instrument. Data about demographic, clinical and social characteristics, and medication use, were collected in Ontario, Canada, from 2003–2011 by trained nurses. Residents with complete admission and 3–6 month follow-up data were included (N = 47,768). Multivariate logistic regression analyses, stratified by gender, explored correlates of new AP drug use upon admission to LTC.

Results

New AP drug users comprised 7 % of the final cohort. Severe cognitive impairment, dementia, and motor agitation were significantly associated with new AP drug use among both sexes. Additionally, behavioural problems, conflicts with staff and reduced social engagement were strong correlates of new AP drug use.

Conclusions

Social factors were as strongly associated with new AP drug use after LTC admission as clinical factors. Strategies to prevent the potential misuse of AP drugs upon LTC admission should consider the social determinants of such prescribing.
Literature
1.
go back to reference Jeste VD, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957–70.CrossRefPubMed Jeste VD, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957–70.CrossRefPubMed
3.
go back to reference Margallo-Lana M, Swann A, O’Brien J, Fairbairn A, Reichelt K, Potkins D, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatr. 2001;16(1):39–44.CrossRef Margallo-Lana M, Swann A, O’Brien J, Fairbairn A, Reichelt K, Potkins D, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatr. 2001;16(1):39–44.CrossRef
4.
go back to reference Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7.CrossRefPubMedPubMedCentral Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7.CrossRefPubMedPubMedCentral
5.
go back to reference Scottish Intercollegiate Guideline Network. Management of patients with dementia: a national clinical guideline. Edinburg: Scottish Intercollegiate Guidelines Network; 2006. Scottish Intercollegiate Guideline Network. Management of patients with dementia: a national clinical guideline. Edinburg: Scottish Intercollegiate Guidelines Network; 2006.
6.
go back to reference Testad I, Aasland AM, Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):916–21.CrossRefPubMed Testad I, Aasland AM, Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):916–21.CrossRefPubMed
7.
go back to reference Zuidema SU, Derksen E, Verhey FR, Koopmans RT. Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. Int J Geriatr Psychiatry. 2007;22(7):632–38.CrossRefPubMed Zuidema SU, Derksen E, Verhey FR, Koopmans RT. Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. Int J Geriatr Psychiatry. 2007;22(7):632–38.CrossRefPubMed
8.
go back to reference Richter T, Meyer G, Mohler R, Kopke S. Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database Syst Rev. 2012;12:CD008634.PubMed Richter T, Meyer G, Mohler R, Kopke S. Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database Syst Rev. 2012;12:CD008634.PubMed
9.
go back to reference DeDeyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia. Neurol. 1999;53(5):946–55.CrossRef DeDeyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia. Neurol. 1999;53(5):946–55.CrossRef
10.
go back to reference Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer’s disease in nursing care facilities: a double-blind randomised, placebo-controlled trial. Arch Gen Psychiatr. 2000;57(10):968–76.CrossRefPubMed Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer’s disease in nursing care facilities: a double-blind randomised, placebo-controlled trial. Arch Gen Psychiatr. 2000;57(10):968–76.CrossRefPubMed
11.
go back to reference Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.CrossRefPubMed Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.CrossRefPubMed
12.
go back to reference Mann E, Köpke S, Haastert B, Pitkälä K, Meyer G. Psychotropic medication use among nursing home residents in Austria: A cross-sectional study. BMC Geriatr. 2009;9(18):18–25.CrossRefPubMedPubMedCentral Mann E, Köpke S, Haastert B, Pitkälä K, Meyer G. Psychotropic medication use among nursing home residents in Austria: A cross-sectional study. BMC Geriatr. 2009;9(18):18–25.CrossRefPubMedPubMedCentral
13.
go back to reference Oborne AC, Hooper R, Li KC, Swift CG, Jackson SH. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing. 2002;31(6):435–9.CrossRefPubMed Oborne AC, Hooper R, Li KC, Swift CG, Jackson SH. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing. 2002;31(6):435–9.CrossRefPubMed
14.
go back to reference Feng Z, Hirdes JP, Smith TF, Finne-Soveri H, Chi I, Du Pasuqier JN, et al. Use of physical restraints and antipsychotic medications in nursing homes: A cross-national study. Int J Geriatr Psychiatry. 2009;24(10):1110–8.CrossRefPubMedPubMedCentral Feng Z, Hirdes JP, Smith TF, Finne-Soveri H, Chi I, Du Pasuqier JN, et al. Use of physical restraints and antipsychotic medications in nursing homes: A cross-national study. Int J Geriatr Psychiatry. 2009;24(10):1110–8.CrossRefPubMedPubMedCentral
15.
go back to reference Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.CrossRefPubMedPubMedCentral Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.CrossRefPubMedPubMedCentral
16.
go back to reference Gellad WF, Aspinall SL, Handler SM, Stone RA, Castle N, Semla TP, et al. Use of antipsychotics among older residents in Veterans Administration nursing homes. Med Care. 2012;50(11):954–60.CrossRefPubMedPubMedCentral Gellad WF, Aspinall SL, Handler SM, Stone RA, Castle N, Semla TP, et al. Use of antipsychotics among older residents in Veterans Administration nursing homes. Med Care. 2012;50(11):954–60.CrossRefPubMedPubMedCentral
17.
go back to reference Rochon PA, Stukel TA, Bronskill SE, Gomes T, Sykora K, Wodchis WP, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007;167(7):676–83.CrossRefPubMed Rochon PA, Stukel TA, Bronskill SE, Gomes T, Sykora K, Wodchis WP, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007;167(7):676–83.CrossRefPubMed
18.
go back to reference Shah S, Carey I, Harris T, Dewilde S, Cooke TG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26(4):423–3. Shah S, Carey I, Harris T, Dewilde S, Cooke TG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26(4):423–3.
19.
go back to reference Foebel AD, Liperoti R, Onder G, Finne-Soveri H, Henrard JC, Lukas A, et al. Use of antipsychotic drugs among residents with dementia in European long-term care facilities: Results from the SHELTER Study. J Am Med Dir Assoc. 2014;15(12):911–7 [Epub ahead of print]. Foebel AD, Liperoti R, Onder G, Finne-Soveri H, Henrard JC, Lukas A, et al. Use of antipsychotic drugs among residents with dementia in European long-term care facilities: Results from the SHELTER Study. J Am Med Dir Assoc. 2014;15(12):911–7 [Epub ahead of print].
24.
go back to reference Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warning on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438–46.CrossRefPubMedPubMedCentral Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warning on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438–46.CrossRefPubMedPubMedCentral
25.
go back to reference Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.CrossRefPubMedPubMedCentral Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.CrossRefPubMedPubMedCentral
26.
go back to reference Maguire A, Hughes C, Cardwell C, O’Reilly D. Psychotropic medications and the transition into care: A national data linkage study. J Am Geriatr Soc. 2013;61(2):215–21.CrossRefPubMed Maguire A, Hughes C, Cardwell C, O’Reilly D. Psychotropic medications and the transition into care: A national data linkage study. J Am Geriatr Soc. 2013;61(2):215–21.CrossRefPubMed
28.
go back to reference Foebel AD, Hirdes JP, Heckman GA, Kergoat MJ, Patten S, Marrie RA, et al. Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. BMC Health Serv Res. 2013;13:457. Foebel AD, Hirdes JP, Heckman GA, Kergoat MJ, Patten S, Marrie RA, et al. Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. BMC Health Serv Res. 2013;13:457.
29.
go back to reference Morris JN, Fries BE, Mehr DR, Hawes C, Phillips C, Mor V, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174–82.CrossRefPubMed Morris JN, Fries BE, Mehr DR, Hawes C, Phillips C, Mor V, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174–82.CrossRefPubMed
30.
go back to reference Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54:M546–53.CrossRefPubMed Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54:M546–53.CrossRefPubMed
31.
go back to reference Hirdes JP, Frijters DH, Teare GF. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96–100.CrossRefPubMed Hirdes JP, Frijters DH, Teare GF. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96–100.CrossRefPubMed
32.
go back to reference Burrows A, Morris JN, Simon S, Hirdes JP, Phillips C. Development of a Minimum Data Set-Based Depression Rating Scale for use in nursing homes. Age Ageing. 2000;29(2):165–72.CrossRefPubMed Burrows A, Morris JN, Simon S, Hirdes JP, Phillips C. Development of a Minimum Data Set-Based Depression Rating Scale for use in nursing homes. Age Ageing. 2000;29(2):165–72.CrossRefPubMed
35.
go back to reference Zuidema SU, De Jonghe JFM, Verhey FRJ, Koopmans RT. Psychotropic drug prescription in nursing home patients with dementia: Influence of environmental correlates and staff distress on physicians’ prescription behaviour. Int Psychogeriatr. 2011;23(10):1632–9.CrossRefPubMed Zuidema SU, De Jonghe JFM, Verhey FRJ, Koopmans RT. Psychotropic drug prescription in nursing home patients with dementia: Influence of environmental correlates and staff distress on physicians’ prescription behaviour. Int Psychogeriatr. 2011;23(10):1632–9.CrossRefPubMed
Metadata
Title
A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents
Authors
Andrea Foebel
Anna Ballokova
Nathalie IH Wellens
Daniela Fialova
Koen Milisen
Rosa Liperoti
John P Hirdes
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2015
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-015-0127-8

Other articles of this Issue 1/2015

BMC Geriatrics 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.